1. Home
  2. NXPL vs INAB Comparison

NXPL vs INAB Comparison

Compare NXPL & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • NXPL
  • INAB
  • Stock Information
  • Founded
  • NXPL 1997
  • INAB 2016
  • Country
  • NXPL United States
  • INAB United States
  • Employees
  • NXPL N/A
  • INAB N/A
  • Industry
  • NXPL Telecommunications Equipment
  • INAB Biotechnology: Pharmaceutical Preparations
  • Sector
  • NXPL Telecommunications
  • INAB Health Care
  • Exchange
  • NXPL Nasdaq
  • INAB Nasdaq
  • Market Cap
  • NXPL 12.4M
  • INAB 14.5M
  • IPO Year
  • NXPL N/A
  • INAB 2021
  • Fundamental
  • Price
  • NXPL $0.57
  • INAB $0.16
  • Analyst Decision
  • NXPL
  • INAB Strong Buy
  • Analyst Count
  • NXPL 0
  • INAB 2
  • Target Price
  • NXPL N/A
  • INAB $3.60
  • AVG Volume (30 Days)
  • NXPL 149.9K
  • INAB 609.1K
  • Earning Date
  • NXPL 05-15-2025
  • INAB 05-07-2025
  • Dividend Yield
  • NXPL N/A
  • INAB N/A
  • EPS Growth
  • NXPL N/A
  • INAB N/A
  • EPS
  • NXPL N/A
  • INAB N/A
  • Revenue
  • NXPL $65,483,000.00
  • INAB N/A
  • Revenue This Year
  • NXPL N/A
  • INAB N/A
  • Revenue Next Year
  • NXPL N/A
  • INAB N/A
  • P/E Ratio
  • NXPL N/A
  • INAB N/A
  • Revenue Growth
  • NXPL 73.44
  • INAB N/A
  • 52 Week Low
  • NXPL $0.43
  • INAB $0.13
  • 52 Week High
  • NXPL $2.30
  • INAB $1.74
  • Technical
  • Relative Strength Index (RSI)
  • NXPL 36.02
  • INAB 39.27
  • Support Level
  • NXPL $0.50
  • INAB $0.15
  • Resistance Level
  • NXPL $0.55
  • INAB $0.17
  • Average True Range (ATR)
  • NXPL 0.07
  • INAB 0.01
  • MACD
  • NXPL 0.01
  • INAB 0.00
  • Stochastic Oscillator
  • NXPL 17.54
  • INAB 11.39

About NXPL NextPlat Corp

NextPlat Corp is an e-commerce and healthcare company. Its e-commerce venues form an effective network serving thousands of consumers, enterprises, and governments. Its healthcare business is focused on improving the lives of patients with complex chronic diseases through patient and provider engagement and their partnerships with payors, pharmaceutical manufacturers, and distributors, offering a broad range of solutions to address the dispensing, delivery, dosing, and reimbursement of clinically intensive, high-cost drugs. The company operates in two segments: e-Commerce Operations involves acquiring and leasing an e-commerce platform; and Healthcare Operations provides TPA, data management, COVID-19 related diagnostics and vaccinations, prescription pharmaceuticals, and Others.

About INAB IN8bio Inc.

IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.

Share on Social Networks: